Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezafungin (Primary) ; Cotrimoxazole; Fluconazole; Fluconazole; Posaconazole
  • Indications Aspergillosis; Invasive candidiasis; Invasive fungal infections; Mycoses; Pneumocystis pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms ReSPECT; The ReSPECT Study
  • Sponsors Cidara Therapeutics

    • Most Recent Events

    • 23 Dec 2022 Planned End Date changed from 1 Mar 2022 to 1 Aug 2024.
    • 23 Dec 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Aug 2024.
    • 20 May 2020 According to a Cidara Therapeutics media release, Johan A. Maertens, M.D., Ph.D., FECCM, (Professor of Internal Medicine and Hematology, University Hospitals Leuven, Leuven, Belgium) is the investigator in this ReSPECT study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top